Can B Corp Acquires Cannabis Patents Valued at $122 Million Through Court Assignment
核心洞察
Can B Corp (搜索) secured ownership of two cannabis patents through its subsidiary Nascent Pharma (搜索), LLC, valued at $122 million for U.S. CBD claims with potential global value reaching $750 million.
The patents cover liquid cannabis formulations with over 95% cannabinoid content and methods for treating conditions including cancer, chronic pain, PTSD, and opioid dependencies.
The intellectual property survived a federal court invalidity challenge and extends protection until 2035, with international applications pending in multiple jurisdictions.
Can B Corp (搜索), a Florida-based health and wellness company specializing in hemp-derived cannabinoid products, announced it has secured ownership and control of two cannabis patents valued at $122 million through its 67% owned subsidiary, Nascent Pharma (搜索), LLC. The patents were previously awarded to United Cannabis Corporation (搜索) and recently assigned to Can B through a court procedure.
Patent Portfolio and Valuation
The two composition and use patents are US 9,730,911 B2 (granted August 15, 2017) and US 10,555,928 B2 (granted February 11, 2020), covering cannabis extracts and methods of preparing the same. An independent third-party valuation team assessed the patents at $122 million in December 2020, applying a 90% discount rate due to the emerging nature of the industry. The valuation included only CBD claims and only in the U.S. market.
Since the initial valuation, the patents have become effective in Canada, Australia, New Zealand, Israel, and Brazil, and have received additional divisional patents in the U.S. The priority date for the patents stems back to October 2013, with pending status in the European Union, India, China, Eurasia, South Korea, Mexico, Japan, and Colombia. Can B believes that if the global THC and CBD markets were added to the valuation, the patents could be worth up to $750 million.
Technical Specifications and Market Coverage
The patents include both a composition of matter patent and a method of use patent. The composition of matter patent covers liquid formulations of cannabis where the present cannabinoids are more than 95% CBD, THC, CBN, CBDa, THCa (搜索), or several combinations thereof. This patent covers beverages, tinctures, vape pen liquids and liquid filled capsules, potentially constituting up to 50% of the hemp and cannabis industry.
The method of use patent utilizes some of the composition of matter combinations to potentially manage debilitating conditions including cancer, IBS, chronic pain, PTSD, anxiety, sleep disorders and opioid dependencies. The patents relate to the extraction of pharmaceutically active components from plant materials and the preparation of botanical drug substances for incorporation into medicaments and pharmaceutical formulations.
Legal Validation and Patent Term
The patents survived an earlier invalidity challenge in Federal Court, where defendants claimed that the patent formulation was a naturally occurring substance, which would not be patentable. The court ruled against this objection, thereby validating the patents. The patent terms are presumed valid by law and extend to 2035.
Company Leadership Perspective
Marco Alfonsi, Can B's Chief Executive Officer, stated, "We are thrilled to be the proud new owners of these extremely important and potentially very valuable cannabis patents. While cannabis stocks have been in a bear market for the past few years, there is no doubt that the industry has witnessed robust growth and has become more and more acceptable, legal and mainstream, despite still being considered a Schedule I drug under the Controlled Substances Act. We believe there is a strong opportunity to monetize these patents as they represent important innovations in this industry."
Can B operates as a health and wellness company providing quality hemp-derived cannabinoid products under its own brands including Canbiola, Seven Chakras, NuWellness, and Pure Leaf Oil. The company utilizes multi-channel distribution to reach consumers through medical facilities, doctor offices, retailers, online platforms and direct sales.